Viamet reports positive Phase II data for vulvovaginal candidiasis drug

Viamet Pharmaceuticals has reported positive results from a Phase II clinical trial (REVIVE) of VT-1161 to treat recurrent vulvovaginal candidiasis (RVVC) patients.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news